We report intrauterine subdural hemorrhage in a preterm infant delivered by cesarean section at 32 weeks following vaginal bleeding of a mother treated with low-molecular weight heparin (LMWH) for deep vein thrombosis. The subdural hematomas were partially calcified, proving antenatal occurrence. Maternal trauma during pregnancy, intrauterine infection, cerebral vascular malformation and congenital coagulopathy as known etiologies of subdural hemorrhage could be ruled out. Intrauterine subdural hemorrhage may be an exceptional complication of maternal LMWH treatment.
Case report
A 47-year-old primipara mother was treated with low-molecular weight heparin (LMWH) for deep vein thrombosis beginning in the 12th week of gestation (dalteparin 200 IE per kg per day, subcutaneously). Vaginal bleeding and contractions occurred at 30 weeks of gestation and she was given steroids for lung maturation. Cesarean section was performed at 32 0/7 weeks of gestation because of recurrent decidual bleeding and a pathologic fetal cardiotocogram. Placenta or vasa praevia, as well as placental abruption, could be ruled out. Before the delivery, high-echodensity lesions were detected on fetal cranial ultrasound examination corresponding to the calcified areas on the postnatal computed tomography. The newborn boy had a birth weight of 1590 g (P10-50), a length of 41.5 cm (P10-50) and a head circumference of 31 cm (P90). Apgar scores were one at 1 min, and nine at 5 and 10 min, respectively. Bag and mask ventilation was necessary during the first minute. Owing to respiratory distress, he was given continuous positive airway pressure therapy using nasal prongs during the first hours of life followed by intubation and mechanical ventilation until day 2. There were no signs of infection, but anemia was present at birth (hematocrit 35%). Examination of the placenta was not contributory. A cranial ultrasound and computed tomography scan on the first day of life showed bilateral subdural hematomas with calcification ( Figure 1) . Coagulation studies showed a slightly increased international normalized ratio of 2.0 (norm for gestational age 0.61 to 1.70), decreased concentration of fibrinogen (0.6 g l À1 ; norm 1.5 to 3.7) and factor XIII (16%; norm 30 to 100), and a thrombocytopenia of 65 000 per mm 3 . The activated partial thromboplastin time and all other coagulation proteins including factor II, factor V, factor VII, factor VIII and factor IX were within the age-related limits; antifactor Xa activity was not measured. Packed red cells were transfused daily on the first few days of life, as well as repeatedly fresh frozen plasma and concentrate of factor XIII because of ongoing subdural bleeding. A subdural drainage was placed into the right-side convexity hematoma on day 6 and removed on day 8. Coagulation parameters normalized (platelet count 276 000 per mm 3 on day 5, international normalized ratio 1.37 and fibrinogen 2.3 g l À1 on day 6, factor XIII 54 and 74% on days 8 and 12, respectively), and a congenital factor XIII deficiency was definitely excluded with family studies. No further intracranial hemorrhage was observed. During the following weeks, the boy showed apneic spells, bradycardia and feeding difficulties with gastro-oesophageal reflux. The head circumference grew slowly, falling from percentile 90 at birth to percentile 10 at discharge. No seizures were noted, electroencephalogram showed marked asymmetry with reduced amplitude in the right hemisphere, acoustic evoked potentials and otoacoustic emissions were absent on the right side, and magnetic resonance imaging showed no vascular or other malformation. The boy was discharged from hospital at the age of 10 weeks (2 weeks after expected term). Further neurologic follow-up revealed left-sided hemiparesis and predominantly right-sided sensorineural hearing loss.
Discussion
Intracranial hemorrhage in the neonatal period is an important clinical problem because of the associated morbidity and mortality. Intraventricular, intracerebellar and subarachnoid hemorrhage are more common in preterm newborns, whereas subdural hemorrhage is more common in term newborns and infants. 1 Subdural hemorrhage is usually a traumatic lesion that occurs during delivery. With improvement in obstetric methods, the incidence has declined and it is nowadays thought to be uncommon, although this incidence may be underestimated, as shown in a recent prospective MRI study in asymptomatic term newborns. 2 Pathogenesis is explained by shearing of bridging veins or other venous structures. Distortion of the infant's cranium as it can occur in instrumental delivery using forceps or vacuum extraction can lead to rupture or tearing of bridging veins or the large venous channels.
In the present case, the onset of hemorrhage is undoubtedly antenatal, proved by fetal ultrasound and the presence of calcification at birth. Intrauterine subdural hemorrhage is rare and there are only few case reports published. [3] [4] [5] Etiology is unknown in many cases. Trauma to the fetal head is the most common factor described, for example maternal falls, assaults or motor vehicle accidents. Other factors are thrombocytopenia, coagulopathies, hepatic disease and intrauterine infections or sepsis with disseminated intravascular coagulation. Exposure to various drugs especially aspirin and other anticoagulants and congenital vascular malformation has also been reported. 4 In the present case, there was no maternal trauma during pregnancy, no evidence for intrauterine infection, hepatic disease or cerebral vascular malformation. However, the mother was treated with LMWH in therapeutic dose for deep vein thrombosis. The initial coagulation abnormalities in the newborn normalized within 2 weeks and therefore an inherent coagulopathy can be ruled out, the findings being consistent with disseminated intravascular coagulation after bleeding. The association of the intrauterine subdural hemorrhage and the LMWH treatment in a mother with recurrent decidual bleeding can be coincidental or causal. As an intrauterine subdural hemorrhage is a rare event, we favor the latter. In pregnant women, LMWH is widely used as prophylaxis or treatment of thromboembolism and is suggested not to cross the placental border. 6 However, alteration of fetal coagulation by maternal LMWH treatment without evidence of placenta crossing has been demonstrated in an animal model. 7 Furthermore, data from controlled trials on placental passage of LMWH in pregnant women are limited, especially when LMWH is used in a (higher) therapeutic dosage. 8, 9 Data are also missing in the case of preterm delivery and associated disturbances of the placenta and the fetus. In the present case, onset of labor and vaginal bleeding occurred 2 weeks before delivery and may have led to transplacental passage of LMWH particularly with regard to the therapeutic dose of LMWH used in this pregnant woman due to deep vein thrombosis. An important shortcoming is the fact that the anti-factor Xa activity in neonatal blood at delivery was not measured.
We suggest that maternal LMWH treatment may be a risk for fetal intrauterine subdural hemorrhage especially in pregnancies complicated by preterm delivery and placental abnormalities. To our knowledge, this is the first instance of an intrauterine subdural hemorrhage possibly related to maternal LMWH treatment. It may be prudent to be more aware of this possible complication. Intrauterine subdural hemorrhage
